Key Milestones Contributing to the Understanding of the Mechanisms Underlying Fibromyalgia

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2020 Jul 26

PMID 32709082

Citations 11

Authors

Geoffrey Littlejohn

Emma Guymer

Affiliations

Soon will be listed here.

Abstract

The promulgation of the American College of Rheumatology (ACR) 1990 criteria for fibromyalgia (FM) classification has significantly contributed to an era of increased research into mechanisms that underlie the disorder. The previous emphasis on putative peripheral nociceptive mechanisms has advanced to identifying of changes in central neural networks that modulate pain and other sensory processes. The influences of psychosocial factors on the dynamic and complex neurobiological mechanisms involved in the fibromyalgia clinical phenotype are now better defined. This review highlights key milestones that have directed knowledge concerning the fundamental mechanisms contributing to fibromyalgia.

Citing Articles

Fibromyalgia: A Review of the Pathophysiological Mechanisms and Multidisciplinary Treatment Strategies.

Jurado-Priego L, Cueto-Urena C, Ramirez-Exposito M, Martinez-Martos J Biomedicines. 2024; 12(7).

PMID: 39062116 PMC: 11275111. DOI: 10.3390/biomedicines12071543.

Effects of Diathermy on Pain in Women with Fibromyalgia: A Randomized Controlled Trial.

Ubeda-DOcasar E, Gonzalez-Gerstner D, Cimadevilla-Fernandez-Pola E, Ojedo-Martin C, Hernandez-Lougedo J, Hervas-Perez J Biomedicines. 2024; 12(7).

PMID: 39062038 PMC: 11275016. DOI: 10.3390/biomedicines12071465.

Expressing emotions, rejection sensitivity, and attachment in patients with fibromyalgia.

Pusuroglu M, Topaloglu M, Hocaoglu C, Yildirim M Turk J Phys Med Rehabil. 2023; 69(3):303-308.

PMID: 37674789 PMC: 10478538. DOI: 10.5606/tftrd.2023.11440.

Fibromyalgia - etiology, diagnosis and treatment including perioperative management in patients with fibromyalgia.

Dizner-Golab A, Lisowska B, Kosson D Reumatologia. 2023; 61(2):137-148.

PMID: 37223370 PMC: 10201378. DOI: 10.5114/reum/163094.

Clinical Characterization of Juvenile Fibromyalgia in a Multicenter Cohort of Adolescents Enrolled in a Randomized Clinical Trial.

Lynch-Jordan A, Connelly M, Guite J, King C, Goldstein-Leever A, Logan D Arthritis Care Res (Hoboken). 2022; 75(8):1795-1803.

PMID: 36537193 PMC: 11284638. DOI: 10.1002/acr.25077.

References

Vaeroy H, Helle R, Forre O, Kass E, Terenius L . Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain. 1988; 32(1):21-26. DOI: 10.1016/0304-3959(88)90019-X. View

Bennett R, Clark S, Walczyk J . A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med. 1998; 104(3):227-31. DOI: 10.1016/s0002-9343(97)00351-3. View

Smythe H, Moldofsky H . Two contributions to understanding of the "fibrositis" syndrome. Bull Rheum Dis. 1977; 28(1):928-31. View

Clauw D . Time to Stop the Fibromyalgia Criteria Wars and Refocus on Identifying and Treating Individuals With This Type of Pain Earlier in Their Illness. Arthritis Care Res (Hoboken). 2020; 73(5):613-616. DOI: 10.1002/acr.24198. View

Russell I, Orr M, Littman B, Vipraio G, Alboukrek D, Michalek J . Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum. 1994; 37(11):1593-601. DOI: 10.1002/art.1780371106. View

Russell I, Vaeroy H, Javors M, Nyberg F . Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum. 1992; 35(5):550-6. DOI: 10.1002/art.1780350509. View

Wolfe F, Clauw D, Fitzcharles M, Goldenberg D, Hauser W, Katz R . 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016; 46(3):319-329. DOI: 10.1016/j.semarthrit.2016.08.012. View

Jensen K, Kosek E, Petzke F, Carville S, Fransson P, Marcus H . Evidence of dysfunctional pain inhibition in Fibromyalgia reflected in rACC during provoked pain. Pain. 2009; 144(1-2):95-100. DOI: 10.1016/j.pain.2009.03.018. View

Wolfe F, Russell I, Vipraio G, Ross K, Anderson J . Serotonin levels, pain threshold, and fibromyalgia symptoms in the general population. J Rheumatol. 1997; 24(3):555-9. View

10.

Yarnitsky D . Conditioned pain modulation (the diffuse noxious inhibitory control-like effect): its relevance for acute and chronic pain states. Curr Opin Anaesthesiol. 2010; 23(5):611-5. DOI: 10.1097/ACO.0b013e32833c348b. View

11.

Graven-Nielsen T, Kendall S, Henriksson K, Bengtsson M, Sorensen J, Johnson A . Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain. 2000; 85(3):483-491. DOI: 10.1016/S0304-3959(99)00308-5. View

12.

McBeth J, Macfarlane G, Benjamin S, Morris S, Silman A . The association between tender points, psychological distress, and adverse childhood experiences: a community-based study. Arthritis Rheum. 1999; 42(7):1397-404. DOI: 10.1002/1529-0131(199907)42:7<1397::AID-ANR13>3.0.CO;2-7. View

13.

Gibson S, Littlejohn G, Gorman M, Helme R, Granges G . Altered heat pain thresholds and cerebral event-related potentials following painful CO2 laser stimulation in subjects with fibromyalgia syndrome. Pain. 1994; 58(2):185-193. DOI: 10.1016/0304-3959(94)90198-8. View

14.

Arroyo J, Cohen M . Abnormal responses to electrocutaneous stimulation in fibromyalgia. J Rheumatol. 1993; 20(11):1925-31. View

15.

Staud R, Robinson M, Price D . Temporal summation of second pain and its maintenance are useful for characterizing widespread central sensitization of fibromyalgia patients. J Pain. 2007; 8(11):893-901. PMC: 2174917. DOI: 10.1016/j.jpain.2007.06.006. View

16.

Yunus M, MASI A, Calabro J, Miller K, Feigenbaum S . Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. Semin Arthritis Rheum. 1981; 11(1):151-71. DOI: 10.1016/0049-0172(81)90096-2. View

17.

DeSantana J, Sluka K . Central mechanisms in the maintenance of chronic widespread noninflammatory muscle pain. Curr Pain Headache Rep. 2008; 12(5):338-43. PMC: 2744440. DOI: 10.1007/s11916-008-0057-7. View

18.

Becker S, Schweinhardt P . Dysfunctional neurotransmitter systems in fibromyalgia, their role in central stress circuitry and pharmacological actions on these systems. Pain Res Treat. 2011; 2012:741746. PMC: 3195783. DOI: 10.1155/2012/741746. View

19.

Affaitati G, Costantini R, Fabrizio A, Lapenna D, Tafuri E, Giamberardino M . Effects of treatment of peripheral pain generators in fibromyalgia patients. Eur J Pain. 2010; 15(1):61-9. DOI: 10.1016/j.ejpain.2010.09.002. View

20.

Grayston R, Czanner G, Elhadd K, Goebel A, Frank B, Uceyler N . A systematic review and meta-analysis of the prevalence of small fiber pathology in fibromyalgia: Implications for a new paradigm in fibromyalgia etiopathogenesis. Semin Arthritis Rheum. 2018; 48(5):933-940. DOI: 10.1016/j.semarthrit.2018.08.003. View